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Purpose: Missense mutations in the splicing factor gene PRPF31 cause a dominant form of retinitis pigmentosa (RP11)
with reduced penetrance. Missense mutations in PRPF31 have previously been shown to cause reduced protein solubility,
suggesting insufficiency of functional protein as the disease mechanism. Here we examine in further detail the effect of
the A216P mutation on splicing function.
Methods: Splicing activity was assayed using an in vivo assay in transfected mammalian cells with rhodopsin (RHO) and
transducin (GNAT1) splicing templates. Pull-down assays were used to study the interaction between PRPF31 and one of
its cognate partners in the spliceosome, PRPF6.
Results: Splicing of RHO intron 3 and GNAT1 introns 3–5 mini-gene templates was inefficient with both spliced and
unspliced products clearly detected. Assays using the RHO minigene template revealed a direct negative effect on splicing
efficiency of the mutant. However, no effect of the mutation on splicing efficiency could be detected using the longer
GNAT1 minigene template or using a full-length RHO transcript, splicing of which had an efficiency of 100%. No unspliced
RHO transcripts could be detected in RNA from human retina. Pull-down assays between PRPF31 and PRPF6 proteins
showed a stronger interaction for the mutant than wild type, suggesting a mechanism for the negative effect.
Conclusions: Splicing of full-length RHO is more efficient than splicing of the minigene, and assays using a full-length
template more accurately mimic splicing in photoreceptors. The RP11 missense mutations exert their pathology mainly
via a mechanism based on protein insufficiency due to protein insolubility, but there is also a minor direct negative effect
on function.
Retinitis  pigmentosa  (RP)  represents  a  large,
heterogeneous group of generally progressive retinal diseases
that initially affect the rod photoreceptors but subsequently
involve both peripheral and central cones, frequently leading
to total blindness. With an incidence of 1 in 3,500 of the
population,  inheritance  may  be  X-linked,  autosomal
dominant, or autosomal recessive. In many cases, the disease
gene  encodes  a  component  of  phototransduction  or  allied
processes with expression confined to the retina, for example
the rod visual pigment (reviewed in [1]), or peripherin-RDS
[2], but not all RP genes show such a restricted pattern of
expression.  In  particular,  mutations  in  four  RNA  splicing
factor genes underlie some autosomal dominant forms of RP,
namely  RP9  (RP9,  OMIM  607331  [3]),  RP11  (PRPF31,
OMIM 600138 [4]), RP13 (PRPF8, OMIM 600059 [5]), and
RP18 (PRPF3, OMIM 607301 [6]). An intriguing aspect to
the  association  of  these  genes  with  retinal  disease  is  that
splicing occurs in every cell of the body so the genes must
have  a  general  housekeeping  function,  yet  the  disease
pathology is restricted to the rod photoreceptors of the retina.
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Mutations in PRPF31 are one of the most common causes
of autosomal dominant RP, with over 30 mutations reported,
including  missense,  deletion,  insertion  and  splice  site
alterations [4,7-11]. Whereas mutations in RP9, PRPF3, and
PRPF8 are fully penetrant, mutations in PRPF31 are not, with
several heterozygous carriers showing no deleterious visual
symptoms  and  only  slightly  abnormal  electroretinograms
[12].  Studies  conducted  on  PRPF31  mRNA  levels  in
lymphoblast cell lines isolated from family members with
either deletion or splice site mutations indicate that penetrance
requires  the  co-inheritance  of  a  low  expressing  wild-type
(WT) allele alongside the mutant allele [13,14], whereas the
presence of a high expressing WT allele is protective. The
disease phenotype would appear to arise therefore only when
the level of WT splicing factor falls below a critical threshold
in rod photoreceptors.
Our previous work [15,16] has investigated the functional
consequences of missense mutations in PRPF31 [4]. With
missense mutations, the mutant protein is almost certainly
produced so the simple answer that the disease arises solely
from a haploinsufficiency of splicing factor protein may not
provide a full explanation for the disease mechanism. Using
a  yeast  complementation  assay,  we  have  previously
demonstrated [15] that the introduction of the human A216P
mutation into the yeast ortholog PRP31p results in reduced
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683growth; the effect of the mutation would appear to be therefore
to modify or reduce the activity of the protein rather than to
abolish it completely. In addition, the mutant protein appears
to be nontoxic in yeast even when highly expressed. Protein
localization  studies  in  mammalian  cells  expressing  His-
tagged  PRPF31  showed  mislocalization  of  the  mutant
proteins,  with  a  substantial  proportion  remaining  in  the
cytoplasm rather than translocated to the nucleus [15]. Further
investigations revealed that this mislocalization was unlikely
to arise from a deficiency in trafficking of the mutant proteins
to the nucleus, but arose rather from an increased tendency for
the mutant proteins to form aggregates in the cytoplasm [16].
The  consequence  of  this  is  a  reduction  in  the  levels  of
PRPF31in the nucleus: an insufficiency of functional protein
in the nucleus may be therefore the primary cause of the
disease.
Our original in vivo assays of splicing function in HEK
293 cells using a bovine rod opsin splicing template failed to
detect any effect of missense mutations on splicing efficiency
[15]. However, Yuan et al. [17] and Mordes et al. [18] have
shown a specific negative effect of two deletion mutations of
PRPF31 on the efficiency of splicing of certain introns in
artificial human minigenes, in particular intron 3 of human
rod opsin (RHO), intron 1 of RDS and intron 3 of FSCN2.
Another study by Rivolta et al. [13] failed however to find any
evidence for a generalized RNA splicing defect caused by
various null-type mutations.
All four splicing genes linked to autosomal dominant RP
encode protein factors required for the formation of stable U4/
U6 snRNPs and for assembly of the U4/U6+U5 tri-snRNP.
Binding  of  this  tri-snRNP  to  the  presplicing  complex
represents a key step in the formation of the spliceosome
proper. PRPF31 binds to the U4 snRNP in the U4/U6 di-
snRNP [19,20] and is thought to form a bridge between the
U4/U6 di-snRNP and U5 by binding to the U5-specific PRPF6
(also known as U5–102 kD protein) [21]. This was confirmed
by RNAi studies in which it was shown that knock-down of
either PRPF31 or PRPF6 inhibited tri-snRNP formation and
led to the accumulation of U5 and U4/U6 [22].
In this study, we have refined our splicing assay system
to examine the effects of the A216P missense mutation in
PRPF31  on  several  splicing  templates  that  include  RHO
intron 3 in a minigene construct plus two templates that more
accurately reflect the real life situation, a full-length human
RHO gene that includes introns 1–4, and a partial rod α-
transducin (GNAT1) gene with introns 2–5. Since any direct
effect  of  splicing  factor  mutations  on  splicing  efficiency
would most likely act via interactions with other components
of the spliceosome, we have examined the interaction via pull-
down assays of WT and mutant PRPF31 with PRPF6, the
other protein component of the tri-snRNP not yet implicated
in RP.
METHODS
Plasmid constructs for splicing assays: For the rod opsin
minigene assays, an exon 3 to exon 4 fragment (E3-E4) from
the human RHO was amplified from human genomic DNA
using NheI- and ClaI-tagged forward and reverse primers (5′-
GCC GGC TAG CAT GTA CAT CCC CGA GGG CCT G-3′
and 5′-CGG CAT CGA TTC ACT TGT TCA TCA TGA TAT
AGA  TGA  C-3′,  respectively)  and  KOD  (Thermococcus
kodakaraensis)  polymerase  (Novagen,  Nottingham,  UK).
This was cloned into the vector pTandem-1 (Novagen) via the
appropriate restriction sites. The PRPF31 cDNA sequence
(WT or A216P) was then transferred from a corresponding
pTriEx-1 construct [15] as a SacII-XhoI fragment to generate
the construct pTan.PRPF31His.RHO E3–4, which expresses
both  His-tagged  PRPF31  protein  and  an  RNA  splicing
template of RHO E3–4. Corresponding constructs expressing
untagged  PRPF31  were  generated  by  first  cloning  the
PRPF31 cDNA sequence into the vector pTriEx-1 (Novagen)
with a stop codon inserted before the His-tag sequence and
then transferring the sequence as a SacII-XhoI fragment into
pTan. RHO E3-E4 as previously described.
Full-length RHO constructs were generated in a stepwise
process because of the relatively large size of the full length
RHO gene of 4.985 kb (from start to stop codons and including
introns). The RHO sequence was amplified as two separate
fragments (E1-E2 with 5′-NheI and 3′-NaeI tags and E2 –E5
with 5′-NaeI and 3′-ClaI tags) from human genomic DNA
using the following primer pairs: E1F (5′-GCG CGC TAG
CAT GAA TGG CAC AGA AGG CCC T-3′) and E2R (5′-
GGA CCA GCC GGC GAG TGG-3′); and E2F (5′-CCA CTC
GCC GGC TGG TCC-3′) and E5R (5′-CGG CAT CGA TTT
AGG CCG GGG CCA CCT G-3′). These two fragments were
cloned  into  the  PCR  vector  pGEM-T  Easy  (Promega,
Southampton,  UK).  Restriction  cloning  was  then  used  to
ligate the fragments together and transfer the assembled gene
sequence  into  NheI/ClaI-cut  pTandem-1.  The  PRPF31
sequence was inserted as before.
Human  GNAT1  constructs  were  generated  by  first
transferring the PRPF31 cDNA sequence into pTandem-1 as
described in the previous paragraph and then inserting an exon
2 to exon 6 GNAT1 fragment amplified from human genomic
DNA  using  HpaI-  and  ClaI-tagged  forward  and  reverse
primers respectively (E2F: 5′-GTT AAC ATG GCC GGT
GAG TCC-3′ and E6R: 5′-ATC GAT TCA CAC TAG CAC
CAT-3′).
Plasmid constructs for protein expression: The N-terminal
domain (PRPF6N, residues 1–307) and two HAT-containing
(half a tetratricopeptide repeat, TPR) domains (PRPF6-M,
residues 307–607, and PRPF6-C, residues 607–941) of human
PRPF6 were amplified from human cDNA and inserted into
the  bacterial  expression  vector  pGEX6P-1  (Amersham
Biosciences, Little Chalfont, UK) via the EcoRI and SalI sites.
The primer pairs used for the amplifications were as follows:
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684for PRPF6N, 5′-GCG CGA ATT CAT GAA CAA GAA CAA
ACC GTT CC-3′ and 5′-CAG CGT CGA CTG TCA ATG
AGG GTT CGT CTC CCG-3′; for PRPF6M, 5′-GCG CGA
ATT CCC CCG CCA GCC TGG ATT GCA TC-3′ and 5′-
CAG CGT CGA CTC ATG CTT TGG GGC AGT CGG C-3′;
and for PRPF6C, 5′-GCG CGA ATT CCC CGC CAG CCT
GGA TTG CAT C-3′ and 5′-GAC GGT CGA CTC AGA
AGG TGT TCT TGA TGC G-3′.
In vivo splicing assays in HEK 293T cells: Human HEK 293T
cells  in  3.5  cm  dishes  were  transiently  transfected  using
GeneJuice  (Novagen)  with  pTandem-1  constructs  which
expressed PRPF31 (WT or mutant) and a splicing template
comprising either the RHO intron 3 mini-gene, the RHO full
length gene, or the GNAT1 partial gene. After 48 h, cells were
washed twice with PBS and used to prepare total cell RNA
using  TRIzol  reagent  (Invitrogen,  Paisley,  UK).
Contaminating DNA carried over from the cell transfection
was  removed  from  the  extracted  RNA  by  treatment  with
RNase-free DNaseI (Roche Diagnostics Ltd., Paisley, UK).
The RNA was quantified using Quant-iT RiboGreen RNA
assay (Invitrogen). RT–PCR was then conducted as follows
to  assay  the  relative  quantities  of  spliced  and  unspliced
transcripts  from  the  splicing  template.  First  strand  cDNA
synthesis was performed with 0.5 µg of total RNA using avian
myeloblastosis virus (AMV) reverse transcriptase and oligo-
p(dT)15 primer (Roche Diagnostics Ltd). This cDNA was
Figure 1. Splicing assays of wild-type
and mutant PRPF31 in transfected HEK
293T cells. A: Assays using RHO intron
3  minigene  splicing  template  (RHO-
MG). As a positive control, cells were
transfected  with  the  splicing  template
only (RHO-MG only). Cells transfected
with WT PRPF31 only gave no products
(negative  control).  Marker  for  the
unspliced  product  was  generated  by
amplification directly from the plasmid
construct using the same primers. B: Bar
graphs show the splicing efficiencies,
derived from the relative band strengths
for cells expressing untagged and His-
tagged PRPF31. Error bars indicate the
standard error of means derived from
four  separate  determinations.  Double
asterisks (**) indicate that the reduced
splicing efficiencies of mutant splicing
factor  compared  to  the  positive  and
negative  controls  are  statistically
significant  (p<0.01).  C:  Assays  using
full  length  RHO  (FL-RHO)  splicing
template.  Analysis  of  all  four  introns
indicates 100% splicing efficiency. No
unspliced  transcript  was  detected  in
cDNA from human retina. D: Assays
using GNAT1 template.
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685diluted to a total volume of 50 µl, and 5 µl aliquots were used
as template in PCR reactions with exonic primer pairs to
amplify across the intervening introns. Thermocycling was
conducted for the minimum number of cycles (generally 20–
25 cycles) to ensure amplification of target sequence remained
in the exponential phase. PCR products were analyzed on
SYBR Green- (Invitrogen Ltd) or ethidium bromide-stained
agarose gels. Relative band strengths were quantified using
Genesnap  software  (Syngene,  Cambridge,  UK)  from  gel
images.
Pull-down assays: WT and A216P His-tagged PRPF31 were
expressed from pTriEx constructs [15] in E. coli Tuner (DE3)
pLacI  cells  (Merck  Biosciences  Ltd.,  Nottingham,  UK),
purified  to  homogeneity  from  inclusion  bodies  under
denaturing  conditions  and  subsequently  refolded  (as
described  in  [16]).  Protein  concentrations  were  estimated
using a Biorad protein assay kit (Bio-Rad UK Ltd., Hemel
Hempstead, UK) against BSA standards.
Glutathione S transferase (GST)-tagged PRPF6 domains
(PRP6F-N,  -M,  -C)  were  expressed  from  pGEX6P-1
constructs  in  E.  coli  BL21  (DE3)  cells  (Amersham
Biosciences).  Liquid  cultures  (Luria-Bertani  broth  with
100 μg/ml ampicilin) were grown at 37 °C to log phase,
induced  with  0.1  mM  Isopropyl-Beta-D-
Thiogalactopyranoside and then grown overnight at 25 °C.
Cells were harvested as cell pellets from 20 ml aliquots and
soluble  extracts  containing  1  ml  GST-tagged  PRP6F-N,
PRP6F-M,  or  PRP6F–C  were  prepared  in  PBS  buffer  by
centrifugation of crude cell lysates.
A 100 µl aliquot of GST-tagged PRPF6-N, PRP6F-M, or
PRP6F–C extract was first bound to 20 µl of 50% glutathione
sepharose beads (Amersham Biosciences) in PBS. Excess
PRPF6 was removed, and the beads were washed once with
PBS and 0.1 nmol of purified His-tagged PRPF31 was added
to give a total volume of 200 μl. The mixture was agitated for
30 min at 4 °C. The beads were then centrifuged and washed
three times with chilled PBS. Bound proteins were eluted with
2 × 10 µl aliquots of reduced glutathione buffer. These were
analyzed on duplicate western blots, one probed with Penta-
His antibodies (Qiagen Ltd, Crawley, UK) and the second
with anti-GST antibodies (Merck Biosciences) followed by
an HRP-conjugated anti-mouse secondary antibody (Perbio
Science UK Ltd., Cramlington, UK). Blots were developed
with  ECL-Plus  HRP  detection  system  (Amersham
Biosciences). Relative band strengths were quantified using
Genesnap software as described in the previous section. Band
quantities were normalized to the strength of the WT band for
each determination. Mean values were estimated from four
independent determinations.
RESULTS
Functional assays of splicing activity: Splicing assays were
designed to examine the efficiency of splicing in transfected
HEK 293T cells expressing either WT or mutant PRPF31
protein exogenously. These cells also express WT PRPF31
(as  well  as  all  the  other  components  of  the  spliceosome)
endogenously. The rationale of the experiment is that the high
level  of  expression  of  the  exogenous  splicing  factor  will
compete with the endogenous splicing factor for incorporation
into the spliceosome and thus reveal any deleterious effects
of the mutations. However, this means that the assays can
detect only dominant effects of the mutations and not effects
due to insufficiency.
Assays  were  conducted  by  transiently  expressing
PRPF31 protein (WT or mutant) plus a splicing template in
HEK 293T cells, extracting total RNA from the cells, and
performing RT–PCR to determine the relative quantities of
spliced  and  unspliced  RNA  products  derived  from  the
exogenous  splicing  template.  Previous  assays  of  PRPF31
splicing activity have relied on cotransfection of the cells with
two plasmids: one expressing the splicing template and the
other  PRPF31  [15,17].  This  has  the  drawback  that  an
undefined proportion of the transfected cells will have taken
up  the  splicing  template  plasmid  alone,  giving  rise  to  a
background of RNA products that have been spliced using
only  endogenous  WT  PRPF31.  To  ensure  that  all  cells
expressing the splicing template were also expressing the
exogenous PRPF31, plasmid constructs were generated in the
pTandem-1  mammalian  dual  expression  vector,  which  is
designed for the coexpression of two open reading frames
from a single bicistronic RNA.
Splicing  assays  using  a  human  rod  opsin  RHO  intron  3
minigene: A minigene similar to that described by Yuan et al.
[17]  was  constructed  that  contained  a  522  bp  sequence
amplified across RHO exon 3 to exon 4 of human genomic
DNA. When pTandem constructs containing this minigene
were used to transfect HEK 293T cells, both spliced (406 bp)
and unspliced (522 bp) products were generated, indicating
inefficient  splicing  of  intron  3  (Figure  1A,  lane  4).  The
splicing  efficiency  was  estimated  as  the  ratio  of  band
fluorescence  (after  staining  with  ethidium  bromide)  for
spliced versus total (spliced + unspliced) transcript, with a
correction  for  the  relative  fluorescence  of  different  size
fragments.  Splicing  efficiency  measured  in  control  cells
expressing the minigene only, where only the endogenous
splicing factor is present, was not affected by addition of
exogenous WT PRPF31 (Figure 1A, lane 2), but splicing
efficiency was reduced by the presence of A216P mutant
PRPF31 (Figure 1A, lane 3). The means±standard error of
measurements obtained from four replicate transfections for
each experiment with either untagged and His-tagged PRPF31
are shown in Figure 1B. For untagged and tagged PRPF31,
therefore, the overall levels of splicing efficiency are similar,
indicating that the presence of a His-tag on the exogenous
PRPF31 does not affect its splicing function. In both cases,
mutant PRPF31 resulted in a statistically significant (p<0.01)
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686reduction in splicing compared to the positive and negative
controls..
Splicing assays using full-length human rod opsin template:
To  ascertain  how  closely  the  splicing  of  a  minigene
approximates to the splicing of a real pre-mRNA template, we
generated transfection constructs that expressed a full-length
RHO gene from the start to stop codons and included all four
introns.  RT–PCR  was  then  performed  on  RNA  from
transfected cells using primer pairs designed to amplify each
intron separately. In contrast to the result with the minigene,
the efficiency of splicing of intron 3 with WT exogenous
splicing factor was substantially greater, approaching a ratio
of 1 for spliced template compared to total template (Figure
1C). When the A216P mutant PRPF31 was used, there was
no reduction in splicing efficiency. Results for introns 1, 2,
and 4 similarly showed that the cells were able to splice these
introns completely even in the presence of mutant PRPF31.
Splicing efficiency of human rod opsin intron 3 in human
retinal tissue: To assess whether the splicing of RHO intron
3 was a limiting factor in the production of fully processed
RHO mRNA in photoreceptors, we generated PCR-amplified
fragments using an exon 3 forward and exon 4 reverse primer
pair from the RHO transcript in mRNA obtained from human
retinal tissue. As shown in Figure 1C, no unspliced product
was obtained, similar to our experiments with the full-length
RHO template, indicating that the latter splicing assays may
model the situation in rod photoreceptor cells more closely
than assays with minigenes.
Splicing assays using partial GNAT1 template: It has been
suggested that small introns may be spliced less efficiently
than larger introns [17]. The human GNAT1 gene has several
small introns of lengths between 89 and 210 bp. We therefore
generated  splicing  constructs  containing  a  partial  gene  of
GNAT1 that comprised exons 2 to 6 and intervening introns,
representing  approximately  one-third  of  the  genomic
sequence. Splicing assays using these constructs indicated that
introns  3  and  5  are  inefficiently  spliced.  However,  no
difference in splicing efficiency was detected when WT or
A216P mutant PRPF31 was co-expressed (results for intron 3
shown in Figure 1D).
Interaction of wild-type and mutant PRPF31 with PRPF6:
Formation of the U4/U6+U5 tri-snRNP component of the
spliceosome  involves  an  interaction  between  PRPF31  (a
component of U4/U6) and PRPF6 (a component of U5) as
demonstrated  by  biochemical  pull-down  experiments  and
yeast two-hybrid studies [21,23]. The PRPF6 protein contains
an N-terminal domain followed by several repeat motifs of
loose consensus classified as HAT domains, a feature present
in  many  RNA  binding  proteins  [24].  Pfam  analysis  [25]
identified  9  such  motifs.  The  interaction  of  PRPF6  with
Figure 2. Pull-down assays showing the
interaction of His-tagged PRPF31 (WT
and A216P mutant) with GST-tagged
PRPF6  domains.  Complexes  between
the two proteins were immobilized with
glutathione sepharose beads and eluted
with reduced glutathione. Panels show
the Western analysis of elution products
using  immobilized  GST-PRPF6N
(amino  acids  1–306),  GST-PRPF6M
(amino  acids  307–607),  and  GST-
PRPF6C (amino acids 607–941). Upper
panels  were  probed  with  α-His.tag
antibody and lower panels with α-GST
antibody. Asterisks (*) indicate the size
of  full-length  GST-PRPF6N,  GST-
PRPF6M,  and  GST-PRPF6C
respectively. Note that the faint band in
the upper panel for the pull-down assay
with  GST-PRPF6N  is  too  small  for
PRPF31-His.  Negative  controls  show
absence of nonspecific binding of His-
tagged PRPF31 to the beads and to GST
tag.  Quantification  of  the  WT  and
mutant  PRPF31  bands  gave  ratios  of
mutant:WT of 4.2±1.4 (for PRPF6M)
and 2.1±0.5 (for PRPF6C). In each case,
the  mean  and  standard  error  was
determined  from  four  separate
determinations.
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687PRPF31 was initially reported to involve the C-terminal HAT
repeats only [21] but has more recently been shown to involve
other HAT repeats [23].
In  this  study,  we  expressed  PRPF6  protein  as  three
separate  domains  comprising  residues  1–307  (PRPF6N),
307–607 (PRPF6M, HAT domains 1–5 according to Pfam
analysis)  and  607–941  (PRPF6C,  HAT  domains  6–9
according to Pfam analysis), together with N-terminal GST
tags. Pull-down experiments with His-tagged WT PRPF31
indicated interactions with PRPF6M as well as PRPF6C, but
not with PRPF6N (Figure 2A), confirming previous results
[21,23]. Quantitative experiments using equivalent quantities
of purified WT and mutant PRPF31 proteins indicated that the
interaction of both PRPF6M and PRPF6C was substantially
stronger with mutant than with WT PRPF31 (Figure 2B).
DISCUSSION
The results presented in this study demonstrate that the A216P
missense mutation in PRPF31 has a dominant deleterious
effect on the splicing of RHO intron 3 transcribed from a
minigene in transfected mammalian cells. Using a similar
minigene  assay,  Yuan  et  al.  [17]  reported  a  comparable
deleterious  effect  in  cells  expressing  truncated  PRPF31
proteins based on two pathogenic frameshift mutations (RP11
families SP117 and AD5 [4]). However, unlike the missense
mutations, where mutant proteins will almost certainly be
expressed in the cells of affected patients, such truncated
proteins may either be rapidly degraded or not produced due
to  nonsense  mediated  decay  (NMD).  This  latter  process
results in the rapid removal of mutant transcripts that contain
a premature termination codon (reviewed in [26]).
The  results  of  the  pull-down  assays  described  here
provide a possible explanation for the dominant deleterious
effect of the missense mutation on function. Our results show
that  the  A216P  mutation  results  in  a  stronger  interaction
between the PRPF31 and HAT-motifs in PRPF6. This will
stabilize  the  U4/U6+U5  snRNP  and  should  promote  the
formation of splicing complex B but could inhibit subsequent
protein-RNA  movements  during  the  later  stages  of  the
splicing cycle. In particular, activation of the spliceosomal
complex B is believed to involve extensive remodeling that
includes  the  removal  of  U4  and  all  tri-snRNP  proteins,
including PRPF6 and PRPF31 (see Figure 3, modified from
[27]).  In  effect,  once  incorporated  into  a  spliceosomal
complex, the mutant protein may inhibit its activation for that
splicing  event  and  the  subsequent  recycling  of  the
spliceosomal components for future splicing events.
While the observation of a dominant deleterious effect of
the A216P missense mutation in PRPF31 could account for
the dominant nature of the RP11 form of disease, it fails to
offer an explanation for the incomplete penetrance of the
disorder in families with obligate carriers of the disease allele.
Reduced  splicing  efficiency  could  only  be  detected  with
minigene  transcripts,  not  full-length  transcripts  from  a
complete gene sequence; splicing from a full-length transcript
appears to occur therefore with full efficiency in the presence
of mutant splicing factor. One possible explanation for this
discrepancy is that greater splicing efficiency may be achieved
with a full-length transcript, because some intrinsic feature in
the  RNA  facilitates  splicing  or  promotes  binding  of  an
extrinsic splicing enhancer. For example, splicing enhancers
may show exonic binding (reviewed in [28]) and will not
function in a minigene assay. Whatever the mechanism, the
assays using the full-length gene construct are more likely to
reflect conditions pertaining in photoreceptor cells than those
using minigenes. This is not to say that the observed splicing
deficiency using the minigene assays is an artifact, rather we
suggest that the design of the assay is such as to reveal a rather
mild  effect  of  the  mutation.  Severe  RP  arises  from
haploinsufficiency but can be prevented if a high-expressing
WT  allele  is  present.  Such  unaffected  carriers  of  RP11
mutations  [29]  may  nevertheless  show  a  mild  retinal
pathology  that  may  be  attributable  to  a  residual
Figure 3. Role of PRPF31 in pre-mRNA
splicing.  PRPF31  is  a  splicing  factor
specific to the U4/U6 snRNP, and its
primary role is to recruit and physically
tether  U5  to  U4/U6  to  yield  the  U4/
U6+U5  tri-snRNP.  This  involves  an
interaction  between  PRPF31  and  the
U5-specific  splicing  factor  PRPF6.
Once incorporated into the spliceosomal
complex B, activation involves loss of
U1 and U4 and all tri-snRNP associated
proteins, including PRPF31 and PRPF6.
The  mutant  PRPF31  proteins  are
predicted to inhibit this activation step
(marked  with  crosses)  and  prevent
recycling of spliceosomal components
for future splicing events.
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688haploinsufficiency.  However,  it  may  also  arise  from  a
reduction in the efficiency of splicing caused by the mutant
PRPF31 protein.
Our results using the GNAT1 splicing template support
previous suggestions that splicing of small introns may be less
efficient than splicing of larger ones [17]. Splicing of both
introns  3  and  5  was  inefficient,  even  with  a  transcript
containing multiple exons and introns. However, even with
these weak introns, our assays failed to detect any effect of
the A216P mutation on splicing efficiency. This is consistent
therefore with our result with the full-length RHO transcript.
Our previous work has shown that another effect of the
missense mutations is to reduce protein solubility and cause
protein mislocation when expressed in transfected cells [15,
16].  This  will  result  in  substantially  reduced  levels  of
functional PRPF31 in the nucleus, which may in turn lead to
an  accumulation  of  unspliced  transcripts  and  aberrant
proteins,  eventually  causing  cell  death.  The  pathological
mechanism whereby PRPF31 missense mutations result in RP
is therefore protein insufficiency, and this may also underlie
the disease pathology of other PRPF31 mutations studied to
date, including gene deletion [7,10], where no mutant protein
can  be  present,  and  mutations  leading  to  premature
termination where NMD of mutant transcripts occurs [13].
Based on the results presented in this report, we have now
found that the missense mutations have a direct effect on
splicing efficiency in addition to the proposed more general
effect  on  PRPF31  sufficiency,  thereby  creating  a  second
mechanism for the pathology. However, it is probable that the
specific effect on splicing makes only a minor contribution to
the development of the disease, since it could not be detected
using either a full-length RHO template or a partial GNAT1
template.  The  major  effect  of  these  mutations  remains
therefore  a  reduction  in  the  amount  of  PRPF31  protein
entering the nucleus.
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